Bertrand Nadel, New Manager of the CALYM Carnot Institute26 octobre 2017,
Bertrand Nadel, Inserm research director, head of the “Genomic Instability and Human Hemopathies” team at the Centre d’Immunologie de Marseille-Luminy, and a member of CALYM translational research teams, succeeds Pascal Deschaseaux at the head of the CALYM Carnot institute.
Bertrand Nadel has been actively involved in the life of CALYM since its inception in 2012, as a member of the Scientific Evaluation and Coordination Committee (COSCI) and a member of the Steering Committee (COPIL).
« Several waves of conceptual and technological revolutions are on their way to profoundly modify the scientific, medical and socio-economic landscape of oncology, prompting an unprecedented public-private dialogue. I seek to continue my investment and commitment in the development of CALYM, taking up the fantastic challenge of the Carnot adventure initiated by Pascal Deschaseaux“, says Bertrand Nadel.
Director of the Provence-Alpes-Côte d’Azur cancer cluster since 2015, Bertrand Nadel was also recently a member of the Inserm « Microbiology, Immunology, Infection” specialized scientific committee and a member of the national scientific committee of the Cancer League.
His research within CALYM focuses on the (epi)genetic mechanisms of oncogenesis in lymphoma and acute lymphoblastic leukemia. It aims to identify pertinent biomarkers of progression, to characterize cancer precursor cells responsible for relapses, particularly in follicular lymphoma, and to develop innovative therapeutic approaches targeting early phases of these cancers in potentially less refractory phases of the disease.
« CALYM is based on a unique positioning of the full R&D value chain, from basic research of excellence to registration clinical trials in the lymphoma field. Faithful to the Carnot spirit that gave birth to our institute, we aim to boost CALYM’s great potential for therapeutic innovation by positioning our consortium as a world-class task force in the lymphoma translational and clinical research field, through building an ever closer partnership with the private sector, where all parties are coordinated actors fully invested in developing progress to the benefit of patients« ,says the new manager.